Table 2.

Freedom from biochemical failure stratified by risk and descriptive statistics.

		1 year (%)	2 year (%)	3 year (%)	4 year (%)	5 year (%)	P-value	Hazard ratio
All patients		100.0	95.5	95.5	95.5	92.7
	High risk	100.0	83.9	83.9	83.9	83.9	0.34	9.3
	Intermediate unfavorable	100.0	90.0	90.0	90.0	90.0		6.8
	Intermediate favorable	100.0	95.2	95.2	95.2	95.2		3.1
	Low risk	100.0	100.0	100.0	100.0	91.7		2.4
	Very low risk	100.0	100.0	100.0	100.0	100.0		1.0
	High risk	100.0	83.9	83.9	83.9	83.9	0.14	7.0
	Intermediate risk	100.0	94.2	94.2	94.2	94.2		2.5
	Low risk	100.0	100.0	100.0	100.0	94.4		1.0
Combined risk groups	High	100.0	86.7	86.7	86.7	86.7	0.07	4.0
	Very low/low/intermediate	100.0	97.9	97.9	97.9	94.4		1.0
Pretreatment PSA	<10	100.0	95.58	95.58	95.58	92.04	0.86	1.0
	10–20	100.0	92.9	92.9	92.9	92.9		1.7
	>20	100.0	100.0	100.0	100.0	100.0		1.8
T-stage	T1c	100.0	97.8	97.8	97.8	94.2	0.19	1.0
	T2a	100.0	85.7	85.7	85.7	85.7		4.7
	Other (T2b +)	100.0	90.0	90.0	90.0	90.0		3.5
Gleason Score	5–6	100.0	100.0	100.0	100.0	95.5	0.03	1.0
	7	100.0	93.4	93.4	93.4	93.4		3.5
	8+	100.0	76.2	76.2	76.2	76.2		12.5
Dose group	Low	100.0	93.8	93.8	93.8	93.8	0.05	11.0
	High	100.0	100.0	100.0	100.0	100.0		1.0
ADT	No ADT	100.0	95.0	95.0	95.0	90.8	0.48	1.6
	ADT	100.0	96.7	96.7	96.7	96.7		1.0

Bold font indicates significant p-value.